Inhibition of RelB by 1,25-dihydroxyvitamin D3 promotes sensitivity of breast cancer cells to radiation

Journal of Cellular Physiology

Volumn 220, Issue 3, 2009, Pages 593-599

  Mineva, Nora D ^a   Wang, Xiaobo ^a   Yang, Sanghwa ^b   Ying, Haoqiang ^a   Xiao, Zhi Xiong J ^a   Holick, Michael F ^a   Sonenshein, Gail E ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; DOXORUBICIN; MANGANESE SUPEROXIDE DISMUTASE; PROTEIN BCL 2; SURVIVIN; TRANSCRIPTION FACTOR RELB; ANTINEOPLASTIC ANTIBIOTIC; BIRC5 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; RADIOSENSITIZING AGENT; RELB PROTEIN, HUMAN; SUPEROXIDE DISMUTASE;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CANCER RISK; CELL STRAIN MCF 7; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG TARGETING; GAMMA RADIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; KNOCKOUT GENE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIATION RESPONSE; RADIOSENSITIVITY; RISK REDUCTION; ADJUVANT CHEMOTHERAPY; ANIMAL; BREAST TUMOR; DRUG ANTAGONISM; DRUG RESISTANCE; FEMALE; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; RADIATION DOSE; RADIATION EXPOSURE; RNA INTERFERENCE; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CALCITRIOL; CELL LINE, TUMOR; CELL SURVIVAL; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, RADIATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICE; MICROTUBULE-ASSOCIATED PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RNA INTERFERENCE; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR RELB; TRANSFECTION;

EID: 67650351201     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21765     Document Type: Article

References (45)

1. Bertone-Johnson ER, Chen WY, Holick MF, Hollis BW, Colditz GA, Willett WC, Hankinson SE. 2005. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 14:1991-1997.
2. Bonetti A, Zaninelli M, Leone R, Cetto GL, Pelosi G, Biolo S, Menghi A, Manfrin E, Bonetti F, Piubello Q. 1998. bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 4:2331-2336.
3. Bottero V, Busuttil V, Loubat A, Magne N, Fischel JL, Milano G, Peyron JF. 2001. Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: A brake to apoptosis in HeLa human carcinoma cells. Cancer Res 61:7785-7791.
4. Bren GD, Solan NJ, Miyoshi H, Pennington KN, Pobst LJ, Paya CV. 2001. Transcription of the RelB gene is regulated by NF-kappaB. Oncogene 20:7722-7733.
5. Burkly L, Hession C, Ogata L, Reilly C, Marconi LA, Olson D, Tizard R, Cate R, Lo D. 1995. Expression of relB is required for the development of thymic medulla and dendritic cells. Nature 373:531-536.
6. Chaudhry M, Sundaram S, Gennings C, Carter H, Gewirtz DA. 2001. The vitamin D3 analog, ILX-23-7553, enhances the response to adriamycin and irradiation in MCF-7 breast tumor cells. Cancer Chemother Pharmacol 47:429-436.
7. Clark GJ, Gunningham S, Troy A, Vuckovic S, Hart DN. 1999. Expression of the RelB transcription factor correlates with the activation of human dendritic cells. Immunology 98:189-196.
8. Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin AS, Jr. 2000. Selective activation of NF-kappa B subunits in human breast cancer: Potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene 19:1123-1131.
9. Demicco EG, Kavanagh KT, Romieu-Mourez R, Wang X, Shin SR, Landesman-Bollag E, Seldin DC, Sonenshein GE. 2005. RelB/p52 NF-kappaB complexes rescue an early delay in mammary gland development in transgenic mice with targeted super repressor IkappaBalpha expression and promote carcinogenesis of the mammary gland. Mol Cell Biol 25:10136-10147.
10. Eisman JA, Sutherland RL, McMenemy ML, Fragonas JC, Musgrove EA, Pang GY. 1989. Effects of 1,25-dihydroxyvitamin D3 on cell-cycle kinetics of T 47D human breast cancer cells. J Cell Physiol 138:611-616.
11. Elstner E, Linker-Israeli M, Said J, Umiel T, de Vos S, Shintaku IP, Heber D, Binderup L, Uskokovic M, Koeffler HP. 1995. 20-epi-vitamin D3 analogues: A novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res 55:2822-2830.
12. Garland CF, Gorham ED, Mohr SB, Grant WB, Giovannucci EL, Lipkin M, Newmark H, Holick MF, Garland FC. 2007. Vitamin D and prevention of breast cancer: Pooled analysis. J Steroid Biochem Mol Biol 103:708-711.
13. Gewirtz DA. 1999. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57:727-741.
14. Ghosh S, May MJ, Kopp EB. 1998. NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16:225-260.
15. Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, Mariani G, Rodriguez J, Carcangiu M, Watson D, Valagussa P, Rouzier R, Symmans WF, Ross JS, Hortobagyi GN, Pusztai L, Shak S. 2005. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23:7265-7277.
16. Ho WC, Dickson KM, Barker PA. 2005. Nuclear factor-kappaB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-kappaB-dependent transcription in cancer cells. Cancer Res 65:4273-4281.
17. Hollis BW. 2008. Measuring 25-hydroxyvitamin D in a clinical environment: Challenges and needs. Am J Clin Nutr 88:507S-510S.
18. Jiang HY, Petrovas C, Sonenshein GE. 2002. RelB-p50 NF-kappa B complexes are selectively induced by cytomegalovirus immediate-early protein 1: Differential regulation of Bcl-x(L) promoter activity by NF-kappa B family members. J Virol 76:5737-5747.
19. Josson S, Xu Y, Fang F, Dhar SK, St Clair DK, St Clair WH. 2006. RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells. Oncogene 25:1554-1559.
20. Kattan Z, Minig V, Leroy P, Dauca M, Becuwe P. 2008. Role of manganese superoxide dismutase on growth and invasive properties of human estrogen-independent breast cancer cells. Breast Cancer Res Treat 108:203-215.
21. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE. 1999. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469.
22. Lazzaro G, Agadir A, Qing W, Poria M, Mehta RR, Moriarty RM, Das Gupta TK, Zhang XK, Mehta RG. 2000. Induction of differentiation by 1alpha-hydroxyvitamin D(5) in T47D human breast cancer cells and its interaction with vitamin D receptors. Eur J Cancer 36:780-786.
23. Lessard L, Begin LR, Gleave ME, Mes-Masson AM, Saad F. 2005. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: An immunohistochemical study. Br J Cancer 93:1019-1023.
24. Mineva ND, Rothstein TL, Meyers JA, Lerner A, Sonenshein GE. 2007. CD40 ligand-mediated activation of the de novo RelB NF-kappaB synthesis pathway in transformed B cells promotes rescue from apoptosis. J Biol Chem 282:17475-17485.
25. Mortimer J, Flournoy N, Livingston RB, Stephens RL. 1985. Aggressive adriamycin-containing regimen (PM-FAC) in estrogen receptor-negative disseminated breast cancer. Results of a Southwest Oncology Group trial. Cancer 56:2376-2380.
26. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ, Jr., Sledge GW, Jr. 1997. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17:3629-3639.
27. Narvaez CJ, Welsh J. 2001. Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells. J Biol Chem 276:9101-9107.
28. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, Wolmark N. 1998. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 90:1361-1370.
29. Paik S, Bryant J, Tan-Chiu E, Yothers G, Park C, Wickerham DL, Wolmark N. 2000. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 92:1991-1998.
30. Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R, Awada A, Wildiers J, Piccart M. 2000. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 18:724-733.
31. Pianetti S, Arsura M, Romieu-Mourez R, Coffey RJ, Sonenshein GE. 2001. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene 20:1287-1299.
32. Rayet B, Gelinas C. 1999. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18:6938-6947.
33. Romieu-Mourez R, Kim DW, Shin SM, Demicco EG, Landesman-Bollag E, Seldin DC, Cardiff RD, Sonenshein GE. 2003. Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors. Mol Cell Biol 23:5738-5754.
34. Shin MH, Holmes MD, Hankinson SE, Wu K, Colditz GA, Willett WC. 2002. Intake of dairy products, calcium, and vitamin d and risk of breast cancer. J Natl Cancer Inst 94:1301-1311.
35. Siebenlist U, Franzoso G, Brown K. 1994. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol 10:405-455.
36. Sonenshein GE. 1997. Rel/NF-kappa B transcription factors and the control of apoptosis. Semin Cancer Biol 8:113-119.
37. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, Sonenshein GE. 1997. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 100:2952-2960.
38. Span PN, Sweep FC, Wiegerinck ET, Tjan-Heijnen VC, Manders P, Beex LV, de Kok JB. 2004. Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin Chem 50:1986-1993.
39. Suhasini M, Reddy CD, Reddy EP, DiDonato JA, Pilz RB. 1997. cAMP-induced NF-kappaB (p50/relB) binding to a c-myb intronic enhancer correlates with c-myb up-regulation and inhibition of erythroleukemia cell differentiation. Oncogene 15:1859-1870.
40. Swami S, Krishnan AV, Feldman D. 2000. 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. Clin Cancer Res 6:3371-3379.
41. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. 2000. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6:127-134.
42. Wang X, Sonenshein GE. 2005. Induction of the RelB NF-kappaB subunit by the cytomegalovirus IE1 protein is mediated via Jun kinase and c-Jun/Fra-2 AP-1 complexes. J Virol 79:95-105.
43. Wang CY, Mayo MW, Baldwin AS, Jr. 1996. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-kappaB. Science 274:784-787.
44. Wang X, Belguise K, Kersual N, Kirsch KH, Mineva ND, Galtier F, Chalbos D, Sonenshein GE. 2007. Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat Cell Biol 9:470-478.
45. Xu Y, Fang F, St Clair DK, Josson S, Sompol P, Spasojevic I, St Clair WH. 2007. Suppression of RelB-mediated manganese superoxide dismutase expression reveals a primary mechanism for radiosensitization effect of 1alpha,25-dihydroxyvitamin D(3) in prostate cancer cells. Mol Cancer Ther 6:2048-2056.